Clinical predictors of relapse following neuroleptic withdrawal
- PMID: 1356490
- DOI: 10.1016/0006-3223(92)90143-n
Clinical predictors of relapse following neuroleptic withdrawal
Abstract
The validity of previously hypothesized predictors of elapse following neuroleptic discontinuation was examined. One hundred sixty-two outpatients, with either Research Diagnostic Criteria schizophrenia or schizoaffective disorder, were discontinued from neuroleptic medication for a 28-day period or until judged to be relapsed. Pre-discontinuation neuroleptic dosage level, the severity of psychotic symptoms, and the presence of dyskinetic movements prior to neuroleptic discontinuation were the predictor variables. Of the 162 patients, 62.7% did not relapse during the study period. There were no differences in the survival rates between the patients withdrawn from oral versus depot neuroleptics. Neuroleptic dosage, but not severity of psychotic symptoms or dyskinetic movements, predicted relapse. These results support the hypothesis that pre-withdrawal neuroleptic dosage level predicts relapse, but fail to validate either severity of psychotic symptoms or presence of dyskinetic movements as predictors of relapse.
Similar articles
-
Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication.Br J Psychiatry. 1990 Oct;157:585-92. doi: 10.1192/bjp.157.4.585. Br J Psychiatry. 1990. PMID: 1983390
-
Methylphenidate challenge as a predictor of relapse in schizophrenia.Am J Psychiatry. 1984 May;141(5):633-8. doi: 10.1176/ajp.141.5.633. Am J Psychiatry. 1984. PMID: 6143506
-
Effects of neuroleptic reduction in schizophrenic outpatients receiving high doses.Can J Psychiatry. 1994 May;39(4):223-9. doi: 10.1177/070674379403900406. Can J Psychiatry. 1994. PMID: 7913872
-
Neuroleptic-induced respiratory dyskinesia.J Neuropsychiatry Clin Neurosci. 1995 Spring;7(2):223-9. doi: 10.1176/jnp.7.2.223. J Neuropsychiatry Clin Neurosci. 1995. PMID: 7626967 Review.
-
[The risk of neuroleptic discontinuation in schizophrenia].Psychiatr Pol. 1999 Jan-Feb;33(1):69-81. Psychiatr Pol. 1999. PMID: 10786216 Review. Polish.
Cited by
-
Relating Spontaneously Reported Extrapyramidal Adverse Events to Movement Disorder Rating Scales.Int J Neuropsychopharmacol. 2015 Jun 26;18(12):pyv064. doi: 10.1093/ijnp/pyv064. Int J Neuropsychopharmacol. 2015. PMID: 26116494 Free PMC article. Clinical Trial.
-
Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia.Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD000459. doi: 10.1002/14651858.CD000459.pub3. Cochrane Database Syst Rev. 2018. PMID: 29409162 Free PMC article.
-
Evaluation of factors influencing medication compliance in inpatient treatment of psychotic disorders.Psychopharmacology (Berl). 2006 Aug;187(2):229-36. doi: 10.1007/s00213-006-0413-4. Epub 2006 May 19. Psychopharmacology (Berl). 2006. PMID: 16710714
-
The neuropharmacology of psychosis.Schizophr Bull. 2007 Jul;33(4):937-46. doi: 10.1093/schbul/sbm063. Epub 2007 Jun 11. Schizophr Bull. 2007. PMID: 17562697 Free PMC article.
-
A virtual reality apartment as a measure of medication management skills in patients with schizophrenia: a pilot study.Schizophr Bull. 2007 Sep;33(5):1162-70. doi: 10.1093/schbul/sbl039. Epub 2006 Sep 6. Schizophr Bull. 2007. PMID: 16956984 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical